Detalhe da pesquisa
1.
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study.
Eur J Haematol
; 109(4): 373-380, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35749094
2.
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study.
Medicina (Kaunas)
; 57(9)2021 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34577823
3.
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.
Front Oncol
; 13: 1162990, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182182
4.
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).
J Pers Med
; 12(3)2022 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35330483
5.
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study.
Clin Lymphoma Myeloma Leuk
; 21(11): e850-e852, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34344639
6.
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.
Leuk Lymphoma
; 61(13): 3255-3258, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32772601